PMDA drug package insert
メトホルミン塩酸塩錠250mgMT「三和」
PMDA Prescription drug · 株式会社三和化学研究所 · package insert Nov 21, 2023
Key facts
| Brand names | メトホルミン塩酸塩錠250mgMT「三和」, メトホルミン塩酸塩錠500mgMT「三和」 |
|---|---|
| Nonproprietary names | メトホルミン塩酸塩 |
| Companies | 製造販売元／株式会社三和化学研究所 |
| Product type | Prescription drug |
| Therapeutic category | ビグアナイド系経口血糖降下剤 |
| Therapeutic category codes | 873962 |
| YJ codes | 3962002F2078, 3962002F3074 |
| Approval numbers | 22700AMX00373000, 22700AMX00374000 |
| Package insert edition | 第2版 |
| Package insert date | Nov 21, 2023 |
| PMDA document key | 300297_3962002F2078_1 |
| PMDA company code | 300297 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- 1–9 Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: